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Structural analysis of a GalNAc-T2 mutant reveals an induced-fit 
catalytic mechanism for GalNAc-Ts 
 
Matilde de las Rivas,[a]^ Helena Coelho, [b],[c]^ Ana Diniz,[b] Erandi Lira-Navarrete,[d] Ismael Compañón,[e] 
Jesús Jiménez-Barbero,[c],[f] Katrine. T. Schjoldager,[d] Eric. P. Bennett,[d] Sergey Y. Vakhrushev,[d] 
Henrik Clausen,[d] Francisco Corzana,[e] Filipa Marcelo,*[b] and Ramon Hurtado-Guerrero*[a],[g] 
Abstract: The family of polypeptide GalNAc-transferases (GalNAc-
Ts) orchestrates the initiating step of mucin-type protein O-
glycosylation by transfer of GalNAc moieties to serine and threonine 
residues in proteins. Deficiencies and dysregulation of GalNAc-T 
isoenzymes have been found to be related to different diseases. 
Recently, we have demonstrated that an inactive GalNAc-T2 mutant 
(F104S), which is not located at the active site, induces low levels of 
high-density lipoprotein cholesterol (HDL-C) in humans. Here, we 
have deciphered the molecular basis for F104S mutant inactivation. 
Saturation transfer difference NMR experiments demonstrate that 
the mutation induces loss of binding to peptide substrates. The 
analysis of the crystal structure of the F104S mutant bound to UDP-
GalNAc, combined with molecular dynamics (MD) simulations, has 
revealed that the flexible loop is disordered and displays larger 
conformational changes in the mutant enzyme than in the wild-type 
(WT) enzyme. 19F-NMR experiments reveal that the WT enzyme 
reaches the active state only in the presence of UDP-GalNAc, 
providing compelling evidences that GalNAc-T2 adopts an UDP-
GalNAc-dependent induced-fit mechanism. The F104S mutation 
precludes the enzyme to achieve the active conformation and 
concomitantly to bind peptide substrates. The present study provides 
new insights into the catalytic mechanism of the large family of 
GalNAc-Ts and how these enzymes orchestrate protein O-
glycosylation. 
Introduction 
Mucin-type (GalNAc-type) O-glycosylation is the most 
differentially and complex regulated type of protein glycosylation, 
and likely the most abundant, with over 80% of all proteins 
predicted to be O-glycosylated.[1] This post-translational 
modification is initiated by a large family (20 in humans) of 
enzymes named polypeptide N-
acetylgalactosaminyltransferases (GalNAc-Ts), which catalyze 
the attachment of a GalNAc residue of the substrate UDP-
GalNAc to Ser/Thr residues of the peptide backbone.  
Although these enzymes have a partial overlap in recognition 
and glycosylation of substrates, a subset of glycosylation sites is 
subjected to site-specific O-glycosylation by individual GalNAc-
Ts. For instance, GalNAc-T3 is responsible for the site-specific 
glycosylation of Thr178 of FGF23, a major regulator of 
phosphate homeostasis[2]. This site-specific glycosylation of 
Thr178 prevents the inactivation of FGF23 by proprotein 
convertase proteases[3], thus mutations in GalNAc-T3 leading to 
a decrease or a complete abolishment of its activity are known 
to cause familial tumoral calcinosis.[3] By a similar mechanism, 
we have recently demonstrated that the loss of GalNAc-T2 
function lowers high-density lipoprotein cholesterol (HDL-C) 
levels in humans.[4] We also identified two independent 
deficiencies in the GALNT2 gene, and one of these involved the 
homozygous missense mutation F104S[4], which was not 
predicted to be deleterious based on conservation and prior 
structural models of the enzyme.[5] Those examples illustrate 
how GalNAc-T isoforms, with seemingly many roles in protein 
glycosylation, have in fact limited non-redundant biological 
functions.[3-4]   
From a structural perspective, GalNAc-Ts are unique among 
glycosyltransferases because in addition to their N-terminal 
catalytic domain, they also possess a unique C-terminal lectin 
domain with both domains being connected by a short flexible 
linker (Figure 1a and Figure S1). There is also an interesting 
structural feature in the catalytic domains of these enzymes, a 
so-called flexible loop, which comprises residues Val360 to 
Gly372 in GalNAc-T2. This loop may adopt different 
conformations during the catalytic cycle, thus rendering the 
enzyme catalytically inactive or active.[5-6] Furthermore, the 
flexible loop dynamics are coupled to the key catalytic residue 
Trp331 mobility that can adopt ‘in’ (inside of the active site) and 
‘out’ (outside of the active site) conformations, which in turn are 
also associated to the active or inactive states of GalNAc-T2, 
[a] Mrs. M de las Rivas, Dr. R. Hurtado-Guerrero 
Instituto de Biocomputación y Fisica de Sistemas Complejos (BIFI), 
BIFI-IQFR (CSIC) Joint Unit, Universidad de Zaragoza, 50018 
Zaragoza, Spain. E-mail: rhurtado@bifi.es 
[b] Mrs. H. Coelho, Mrs. A. Diniz, Dr. F. Marcelo 
UCIBIO, REQUIMTE, Departamento de Química, Faculdade de 
Ciências e Tecnologia, Universidade de Nova de Lisboa, 2829-516 
Caparica, Portugal. E-mail: filipa.marcelo@fct.unl.pt 
[c] Mrs. H. Coelho, Prof. J. Jiménez-Barbero 
 CIC bioGUNE, Bizkaia Technology Park, Building 801A, 48170 
Derio, Spain; Departament of Organic Chemistry II, Faculty of 
Science & Technology, University of the Basque Country, 48940 
Leioa, Bizkaia, Spain 
[d] Mrs. E. Lira-Navarrete, Dr. K. T. Schjoldager, Dr. E. P. Bennett, Dr. 
S. Y. Vakhrushev, Prof. H. Clausen  
           Copenhagen Center for Glycomics, Department of Cellular and 
Molecular Medicine, School of Dentistry, University of Copenhagen, 
Copenhagen, Denmark. 
[e]       Mr. I. Compañón, Dr. F. Corzana 
           Departamento de Química, Universidad de La Rioja, Centro de 
Investigación en Síntesis Química, E-26006 Logroño, Spain. 
[f]        Prof. J. Jiménez-Barbero 
           Ikerbasque, Basque Foundation for Science, Maria Diaz de Haro 13, 
48009 Bilbao, Spain. 
[g] Dr. R. Hurtado-Guerrero 
           Fundación ARAID, 50018, Zaragoza, Spain. 
[^]             Mrs. M de las Rivas and H. Coelho contributed equally to this work 
           Supporting information for this article is given via a link at the end of 
the document. 
10.1002/chem.201800701
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
FULL PAPER    
 
 
 
 
 
respectively.[5-6] Crystal structures of GalNAc-Ts can be used as 
a platform to infer how mutations on these enzymes might lead 
to loss-of-function.[5-7] However, this is not always 
straightforward and further experimental work in solution to infer 
the dynamic behavior of the global system is required. The 
F104S mutant in GalNAc-T2 precisely illustrates this idea since 
Phe104 is not located at the active site, but placed at a distance 
of ~5 Å from the flexible loop and the critical Mn+2 binding site, 
which is formed by the D224xH226 residues and His359 (Figure 
1b).[5] Thus, it is not obvious how mutation of Phe to Ser impairs 
GalNAc-T2 catalytic activity.  
Figure 1. States of the flexible loop and location of Phe104: a) Superposition 
of the overall crystal structure of GalNAc-T2 in complex with UDP and the 
glycopeptide MUC5AC-13[5] (closed conformation shown in white color; see 
PDB entry 5AJP), with the crystal structure of GalNAc-T2 in complex with 
UDP[7b] (open conformation also shown in white color; see PDB entry 2FFV). 
The GalNAc moiety of MUC5AC-13 is colored in orange. UDP and MUC5AC-
13 are depicted as orange and green carbon atoms, respectively. The Mn+2 
binding D224xH226 motif and His359 are shown as black carbon atoms. The 
flexible loop is depicted in blue (open conformation) and yellow (closed 
conformation) for the PDB entries 2FFV and 5AJP, respectively. Mn+2 is 
shown as a pink sphere. b) Close-up view of the active site (closed 
conformation; PDB entry 5AJP) showing the distance of Phe104 (in blue) to 
the flexible loop (in yellow) and the His226 (in black). The backbone structure 
is shown in grey while the other structural features and amino acids are shown 
in the same colors as in panel a. 
Herein, we show that the F104S mutation in GalNAc-T2 
constrains the flexible loop and renders the enzyme locked in an 
inactive state unable to bind the acceptor peptide substrate. We 
have combined saturation transfer difference NMR (STD-NMR), 
19F-NMR spectroscopy, X-ray crystallography and molecular 
dynamics simulations to demonstrate that Phe104 fine-tunes the 
dynamic behavior of the flexible loop by establishing a CH-π 
interaction with the side-chain of Arg362, which is located at the 
flexible loop. This interaction appears to be the key to maintain 
the flexible loop in the required closed conformation that leads to 
the active state of the enzyme. Therefore, the inability of the 
mutant to adopt the active state disrupts the peptide substrate 
recognition and prevents O-glycosylation. Finally, we have 
experimentally demonstrated that GalNAc-T2 adopts an UDP-
GalNAc-dependent induced-fit mechanism for catalysis and 
suggest that the behavior of the flexible loop can be extrapolated 
to the rest of the members of the GalNAc-T family.   
Results and Discussion 
The GalNAc-T2 F104S mutant does not bind to peptides. 
The available data based on kinetic assays of the F104S mutant 
cannot explain the molecular basis of the inactivation of the 
GalNAc-T2 mutant F104S against protein substrates.[4] Since 
Phe104 is not located at the active site (Figure 1b), its mutation 
to Ser must induce conformational changes of the residues 
located in the active site, affecting either the binding of the 
mutant to the substrates or the catalytic turnover. To rule out 
one of these two hypotheses, we have determined the binding of 
the GalNAc-T2 WT enzyme and the F104S mutant to UDP-
GalNAc and a peptide substrate applying tryptophan 
fluorescence spectroscopy and STD-NMR experiments, 
respectively. In addition, we have also conducted a thermal shift-
assay experiment on both enzymes to evaluate the differences 
in the protein stability.[8] The data in Figure 2 shows that the WT 
enzyme is more stable than the F104S mutant (denaturation 
temperatures of T0 of 47 ± 0.09 °C and 42 ± 0.05 °C, 
respectively), implying that the mutation leads to a significant 
decrease on the stability of the mutant (Figure 2a). The 
tryptophan fluorescence spectroscopy analysis of UDP-GalNAc 
binding revealed that both the WT enzyme and the F104S 
mutant bind to the donor sugar nucleotide, with the Kd of UDP-
GalNAc to the mutant being 1.7-fold higher than the Kd 
determined for the WT enzyme (Figure 2b and Figure S2). In 
contrast, STD-NMR experiments recorded for the peptide 
a)                                                                                      
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substrate MUC5AC (GTTPSPVPTTSTTSA) only showed WT 
GalNAc-T2 binding to the MUC5AC peptide (Figure S3). No 
STD signal response was observed for MUC5AC in presence of 
the mutant F104S (Figure S3 and Table S1). This result points 
out that the mutant is not able to properly recognize and bind the 
peptide substrate, thus explaining the previously observed 
inactivity of the mutant towards protein substrates such as 
phospholipid transfer protein (PLTP) and ApoC-III[4]. In addition, 
the WT enzyme showed clear STD-NMR signals for the protons 
of Valine and Proline amino acids from the sequence “PSPVPT” 
(where the underlined Thr is the main acceptor site on this 
peptide for GalNAc-T2) than for the rest of peptide sequence 
(Figure S4). The identified STD-NMR epitope is consistent with 
the sequence preferences of GalNAc-T2, particularly having a 
Pro residue preceding the site of glycosylation[9]. Hence, while 
there are no major differences in UDP-GalNAc recognition 
between the WT enzyme and the F104S mutant, the dramatic 
differences in activity are accounted for either the inability or 
poor affinity of the F104S mutant to bind the peptide substrates. 
 
 
Figure 2. Stability and binding properties of the WT enzyme and the F104S 
mutant: a) Thermal denaturation curves of the WT enzyme and the F104S 
mutant as monitored by 1-anilino-8-naphthalene sulfonate (ANS) fluorescence. 
b) Kd values for sugar nucleotide binding determined from the tryptophan 
fluorescence intensity as a function of UDP-GalNAc concentrations.  
Phe104 controls the inactive-to-active state transition. To 
elucidate the molecular basis for the loss of acceptor peptide 
substrate binding induced by the F104S mutation, we obtained 
tetragonal crystals of this mutant in complex with UDP that were 
subsequently soaked with UDP-GalNAc. The resulting crystals 
allowed us to solve the structure at 2.70 Å resolution (Table S2). 
Within the asymmetric unit, two molecules of the F104S mutant 
were present. The crystal structure shows a compact structure 
with the typical N-terminal GT-A fold and a C-terminal lectin 
domain (Figure 3).  
Figure 3. Overall crystal structure of the F104S mutant bound to UDP-
GalNAc: Cartoon representation of the overall F104S mutant in complex with 
UDP-GalNAc and the WT enzyme either in complex with UDP[7b] (PDB entry 
2FFV) or UDP/MUC5AC-13[5] (PDB entry 5AJP). The proteins and the GalNAc 
moiety of MUC5AC-13 are colored in grey and orange, respectively. 
UDP/UDP-GalNAc is shown as orange carbon atoms. MUC5AC-13, the 
flexible loop, and the α1-α2 loop are depicted as green, yellow and blue 
ribbons, respectively. The Phe104 is shown as sticks in blue. Mn+2 is depicted 
as a pink sphere. (insert) Surface representation of the above complexes 
showing inactive and active states. Colours are the same as above. Note that 
we do present the overall structure of both F104S molecules because there 
are some differences between them. This is because the asymmetric unit 
contains two molecules of the F104S mutant.  
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The flexible loop in both F104S molecules of the asymmetric unit 
is highly disordered (Figure 3, 4, 5 and Figure S5), exposing the 
substrate UDP-GalNAc to the solvent. In these structures the 
flexible loop displays the open conformation that restraints the 
enzyme in an inactive state, resembling the structure of the WT 
enzyme in its inactive state (see PDB entry 2FFV; Figure 3, 4 
and 5). This conformation is opposed to that presenting the 
active state. In the active state the flexible loop displays a closed 
conformation that functions to cover UDP-GalNAc or UDP from 
the solvent (e.g. see PDB entries 5AJP, 4D0T and 4D0Z; Figure 
3). This geometrical arrangement is required for the binding of 
the peptide/protein substrates[5, 6c]. This closed conformation of 
the flexible loop is further stabilized by interactions of His365 
and Phe369 with Trp331 (in-conformation) and by additional 
interactions with the donor substrate UDP-GalNAc (Figure 5)[6c]. 
In fact, the fully active state can only be reached when both the 
flexible loop and Trp331 adopt the closed geometry and the “in-
conformation”, respectively.  
Figure 4. Close-up view of the binding site of the complexes in Figure 3. 
UDP/UDP-GalNAc is shown as orange carbon atoms. MUC5AC-13, the 
flexible loop, and the α1-α2 loop are depicted as green, yellow and blue 
ribbons, respectively. Val360/Arg362, Phe104 and Trp331 are shown as sticks 
in yellow, blue and black carbon atoms, respectively. Other residues 
interacting with Phe104 are shown as brown carbon atoms. Both Phe104 and 
residues interacting with it are magnified. Trp331 is shown in an “out and in 
conformations”. Note that the Trp331 in both F104S molecules present in the 
asymmetric unit shows “out and in conformations”.  
UDP-GalNAc in the inactive F104S mutant is shown adopting 
two potential conformations as previously described for UDP 
(Figure 3, 4 and 5)[5, 7b]. The first conformation is where the 
uridine moiety is bound in an “inverted” conformation, 
compatible with UDP-GalNAc entrance in the active site. The 
second conformation is for the enzyme in an active state, having 
a conformation suited for catalysis (see also PDB entry 5AJP; 
Figure 4). It should also noted that, the crystal structure of 
GalNAc-T2 in complex with UDP shown in the PDB entry 2FFV, 
shows the uridine moiety in the “inverted” conformation, 
although this geometry is likely related to product release 
(Figure 4). 
A detailed analysis of the F104S mutant structure reveals a lack 
of density for Ser104 and for most of the residues of the loop 
between helical α1 and α2 (named hereafter α1-α2 loop). In the 
WT enzyme, Phe104 establishes hydrophobic and stacking 
interactions with Ala151/Ile256/Val360 and Phe261, likely 
stabilizing the location of both the α1-α2 and the flexible loops, 
in the inactive state (Figure 4). The disordered states of both 
loops in the inactive mutant might also explain why this structure 
is less stable than the WT enzyme (see above). In the active 
state of the enzyme, Phe104 also establishes a CH-π interaction 
with the side-chain of Arg362 located in the flexible loop (Figure 
4). This stabilizing interaction appears to be a key feature 
rendering the closed conformation of the flexible loop. In 
contrast, the polar Ser104 residue likely disrupts the interactions 
with the hydrophobic/aromatic residues, leading to the 
destabilization of the α1-α2 loop and the inability for the flexible 
loop to reach the closed conformation. Therefore, the obtained 
data suggest that when Phe104 is replaced by a serine residue  
Figure 5. Close-up view of the sugar nucleotide and peptide binding site of the 
F104S-UDP-GalNAc and WT-UDP-5S-GalNAc-mEA2 complexes. Residues 
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and the sugar nucleotides are depicted with the same colors as shown in 
Figure 3 and 4. Hydrogen bond interactions are shown as dotted green lines. 
(Ser104), the enzyme is not able to reach the active state, even 
in the presence of UDP-GalNAc due to the lack of the essential 
Phe104/Arg362 CH-π interaction, which provides the additional 
stabilization required to induce the closed conformation of the 
flexible loop. Interestingly, most of the residues interacting with 
Phe104, Ile256/Val360/Phe261/Arg362, are highly conserved 
among different GalNAc-Ts (Figure S6). This fact suggests that 
the flexible loop behavior and the corresponding activation 
mechanism via the Phe104/Arg362 CH-π interaction is 
conserved across most GalNAc-T isoenzymes. 
Regarding the UDP-GalNAc recognition, the binding sites of 
both the F104S mutant and the WT enzyme in the active form 
show almost equivalent interactions, explaining the similar Kd 
values obtained for this sugar nucleotide (Figure 2b). The 
interactions with UDP-GalNAc are mostly based on hydrogen 
bonds with the surrounding protein residues, whereas the 
pyrophosphate is involved in the coordination of the Mn+2 ion, 
together with the residues of the D224xH226 motif and His359 
(Figure 5). Minor additional interactions are found for the WT 
enzyme in the active form (e.g. hydrogen bond interactions with 
Gly332 and Tyr367; Figure 5), which is in agreement with the 
slightly better affinity for UDP-GalNAc on the WT enzyme versus 
the mutant (1.7-fold).   
The flexible loop in the F104S mutant displays large 
conformational changes. To understand how the mutation 
F104S disturbs the dynamics of the flexible loop, we ran 200 ns 
molecular dynamics (MD) simulations in explicit water on both 
the WT enzyme and the F104S mutant in the presence of UDP-
GalNAc. The data revealed that the flexible loop of the mutant 
displayed significantly larger conformational changes, with root-
mean-square-deviation (RMSD) ranging between 1-5.3 Å, as 
compared to 1-3 Å deviations for the WT enzyme (Figure 6a). 
This trend was also shown in the variation of the Cα distances 
between the Phe104/Ser104 residues and Val360. While a 
shorter distance of 5.7 ± 1.4 Å was found for Phe104-Val360, 
highly variable and larger distances (ranging from 4.5 to 16 Å) 
were found for Ser104-Val360 (Figure 6b and 6c). We also 
determined the distance distributions for Arg362/Phe104, and 
Arg362/Ser104-Cα pairs (Figure 6b). The average distance of 
4.7 ± 1.4 Å found for the WT enzyme suggests the presence of 
stabilizing hydrophobic interactions between the aromatic ring of 
Phe104 and the side-chain of Val360. In contrast, two 
populations were found for the mutant: a minor population, with 
distances ranging between 3.5-7 Å, and a major population, with 
highly oscillating distances, between 7.5-17 Å (Figure 6b). 
These results also point out that the flexible loop and the α1-α2 
loop are much more structured in the WT enzyme than in the 
mutant and that these structural entities remain at a closer 
distance in the WT enzyme than in the mutant. Therefore, 
according to the MD analysis, the closed conformation of the 
flexible loop in the inactive mutant would rarely form.   
 
Figure 6. Molecular dynamics simulations on the WT enzyme and the F104S 
mutant: a) The RMSD (root-mean-square deviation) values calculated from 
200 ns molecular dynamics (MD) simulations for the flexible loop indicates that 
this structural motif is more flexible in the mutant (green plot) than in the WT 
enzyme (blue plot). Note that the RMSD was obtained using the fixed 
coordinates of the flexible loop from the PDB entry 4D0T. b) This is also 
evidenced by larger distance distribution between Ser104 (Cα) and Val360 
(Cδ)/Arg362 (Cε) in the mutant (bottom) compared to the corresponding 
distances (Phe104-Val360 and Phe104-Arg362) found in the WT enzyme (top). 
c) The center of mass of the π-electron system of Phe104 was used to 
calculate the distances. 
19F labeling of the T375C and F104S-T375C variants for NMR 
experiments. To experimentally monitor the dynamics of flexible 
loop, we also performed 19F-NMR spectroscopy experiments on 
the WT enzyme and on the F104S mutant. 19F chemical shifts 
are highly sensitive to changes in the local conformational 
environment and provide a simple and well-established 
approach for studying biomolecular structure, conformation, and 
dynamics.[10] To introduce the required 19F label, Thr375 was 
mutated to the more nucleophilic Cys residue, in both the WT 
enzyme and the F104S mutant. This residue was selected for 
several reasons: i) it is exposed and accessible to be modified 
and WT GalNAc-T2 and the F104S mutant contain only two free 
buried cysteines at the active site; ii) it is fairly close to the 
flexible loop but sufficiently far away from the Mn2+ ion to 
minimize strong paramagnetic relaxation enhancements; and iii) 
the crystallographic analyses indicates that Thr375 would be 
sensitive to the flexible loop dynamics and may adopt different 
conformations depending on the geometry of the flexible loop 
(open or closed). It should be noted that Thr375 in the PDB 
entry 2FFV is 10 Å away from the same residue in PDB entry 
5AJP (Figure 7a). Thus, both the WT enzyme and the F104S 
mutant variants containing the T375C mutation were produced 
(see the experimental section). The 19F label was subsequently 
introduced into the T375C and the F104S-T375C variants using 
3-bromo-1,1,1-trifluoroacetone (BFA) (see the experimental 
section).[10] A single SCH2(CO)CF3 adduct  was obtained for 
each enzymes (GalNAc-T2* and F104S*) as shown by trypsin 
digestion and MS fragmentation studies (Figure 7b). While the 
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GalNAc-T2* was 100% labeled, the F104S* was only 93% 
modified (Figure 7b). The activity of GalNAc-T2* was evaluated 
and compared with that obtained for the WT enzyme (Figure 7c 
and the experimental section). GalNAc-T2* still remained active 
giving ~50% activity against MUC1 peptide compared to the WT 
enzyme. 
Figure 7. Labeling of the T375C and F104S-T375C variants with BFA: a) 
Close-up view of the active sites of the PDB entries 2FFV and 5AJP, which 
are in an inactive and active states, respectively. The flexible loop adopting an 
open (2FFV) and closed conformation (5AJP) is colored in yellow. The 
MUC5AC-13 is depicted as sticks in green carbon atoms whereas the 
GalNAc-moiety is in orange carbon atoms. UDP is colored in orange. The α 
and β secondary structures are brown and grey for the PDB entries 2FFV and 
5AJP, respectively. Thr375 is depicted as sticks as brown (2FFV) and blue 
(5AJP) carbon atoms. Note that DSSP[11] extracts from the 3D structure that 
Thr375 in the PDB entry 2FFV is part of the flexible loop whereas in the PDB 
entry 5AJP is located in α10. b) MS/MS spectrum of the precursor ions at m/z 
654.6346, z=3+ assigned to 363KQHPYTFPGGSGCVFAR379 peptide 
containing the 19F label at the position C375 (left) and relative quantification 
based on the extracted ion chromatogram between peptides with and without 
the 19F label at the position C375 (right). The experiments were performed for 
the GalNAc-T2* (top) and F104S* (bottom). c) Specific activity of the WT 
enzyme and GalNAc-T2* using the MUC1 peptide as acceptor substrate. The 
data represent means ± S.D. for three independent experiments.  
19F NMR experiments reveal that GalNAc-T2 adopts an UDP-
GalNAc dependent induced-fit mechanism. With both WT and 
mutant proteins labeled with BFA, we first screened enzymes 
activity against MUC5AC by 1H-NMR experiments confirming 
that only GalNAc-T2* and not the F104S* mutant was able to 
glycosylate MUC5AC (Figure S7 and S8).  
 
To evaluate whether the Cys375 19F label was sensitive to the 
dynamics of the flexible loop upon substrate binding, we firstly 
performed 19F-NMR experiments on GalNAcT2*. A set of 
experiments using distinct combinations of UDP-GalNAc, MnCl2 
and MUC5AC were used (Figure 8 left and middle panel and 
Figures S9 and S10 in SI). The 19F-NMR spectra of unbound 
GalNAcT2* (Figure 8, left and middle panels blue tracings) 
showed two 19F resonances at δ = −84.0 ppm and δ = −84.3 
ppm. The upfield 19F signal at δ = −84.3 ppm remained 
unperturbed for all combinations of added substrates, which we 
attribute to the oligomeric GalNAc-T2* state. The linewidth of the 
upfield oligomer 19F peak (δ = −84.3 ppm) is 161 Hz, significantly 
larger than that observed for the monomer at δ = −84.0 ppm 
(111 Hz), which is consistent with a reduced relaxation time of 
the oligomeric enzyme[12]. We have previously demonstrated by 
small-angle X-ray scattering experiments that GalNAc-T2 forms 
oligomers that are not fully catalytically active.[5] This may 
explain the lack of perturbation of this particular NMR signal 
under different substrate combinations. After addition of UDP-
GalNAc and Mn+2 to GalNAc-T2*, the 19F-NMR resonance at δ 
−84.0 ppm almost vanished and a new signal appeared at δ =  
−83.7 ppm (Figure 8, left panel and middle panel red tracing). It 
is remarkable that the exchange between these two 19F-NMR 
resonance (−84.0 ppm and −83.7 ppm) only occurs in the 
presence of UDP-GalNAc and Mn+2. Indeed, in the absence of 
UDP-GalNAc, the addition of Mn+2 (Figure 8, left panel and 
middle panel green tracing) or the peptide MUC5AC (Figure 8, 
left panel and middle panel grey tracing) did not induce any 
appreciable perturbation in the 19F-NMR spectrum of GalNAc-
T2*. This result strongly suggests that the 19F-NMR resonances 
at δ = −84.0 ppm and δ = −83.7 ppm correspond to the open and 
closed conformations of the flexible loop, respectively. These 
two populations are in slow exchange on the NMR chemical shift 
timescale and thus detected as two resonances. An additional 
set of experiments was also recorded in the presence of UDP 
and Mn+2 (Figure S11), giving similar results as obtained for 
addition of UDP-GalNAc. However, the exchange between the 
open and closed conformations of the flexible loop was not so 
pronounced compared to that in the presence of UDP-GalNAc. 
All together, our data show that UDP-GalNAc is absolutely 
required for the interconversion between the open and closed 
conformations of the flexible loop and that UDP-GalNAc 
stabilizes the closed conformation better than UDP (see Figure 
S9-S11). In fact, as deduced from the analysis of the crystal 
structure (see Figure 5 and panel corresponding to the active 
site of the PDB entry 4D0Z), UDP-GalNAc displays additional 
interactions with the enzyme through the GalNAc moiety. The 
fact that UDP does not completely exchange the population of 
the enzyme conformations towards the fully active state is 
consistent with its role as a reaction product after catalysis.  
The described 19F-NMR experiments provide a compelling 
evidence that GalNAc-T2 follows an induced-fit mechanism and 
support our previously proposed ordered bi–bi kinetic 
mechanism for this enzyme.[6c] The induced-fit mechanism has 
been also proposed for distant glycosyltransferases such as 
B4GALT1 and the lactose synthase by applying X-ray crystal 
structure studies[13]. In this mechanism, GalNAc-T2 is always in 
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the inactive state (open flexible loop) and only exchanges to the 
active state (closed flexible loop) in the presence of UDP-
GalNAc/MnCl2. In contrast to the earlier hypothesis,[6c] our new 
data does not support the existence of an equilibrium between 
the inactive and active states in the absence of UDP-
GalNAc/MnCl2. The uridine moiety of UDP-GalNAc might also 
shift its orientation from the “inverted” conformation to the typical 
geometry required for catalysis during the transition from the 
inactive to the active state of the enzyme. Only after the enzyme 
is in the active state, the peptide can bind, and the catalysis can 
take place. 
The inactive-to-active state transition of the flexible loop is 
hindered in the F104S mutant.  
The same set of experiments was performed for the F104S* 
construct (Figure 8 right panel and Figure S12-S13). In this case, 
no alterations in the 19F-NMR spectrum were observed for any 
substrate addition. In particular, the addition of UDP-GalNAc or 
UDP did not induce any perturbation of the 19F resonance at δ = 
−84.0 ppm (Figure 8 and S12-S13). This result also confirms the 
assignment of the peak at δ = −84.0 ppm to the open 
conformation of the flexible loop and highlights that this 
conformation is associated to the inactive form of GalNAc-T2. 
Furthermore, the 19F-NMR experiments demonstrate that the 
flexible loop in F104S* is fixed in the open conformation, 
precluding the binding to peptide substrates and their 
glycosylation. Overall, the 19F-NMR experiments provide the 
molecular basis to explain why the F104S mutant does not 
recognize peptides and in turn is inactive. 
 
 
Figure 8. 19F-NMR Spectra of GalNAc-T2* and F104S* showing the open and closed loop conformations as a function of donor and acceptor substrate additions: 
(Left panel) Blue color corresponds to unliganded GalNAc-T2*. The green color corresponds to GalNAc-T2* in the presence of MnCl2 (225 µM). Red color 
corresponds to GalNAc-T2*, MnCl2 (225 µM) and UDP-GalNAc (225 µM). Grey color corresponds to GalNAc-T2*, MnCl2 (225 µM), UDP-GalNAc (225 µM) and 
MUC5Ac (150 µM). (Middle panel) Blue color corresponds to unliganded GalNAc-T2*. Grey color corresponds to GalNAc-T2* and MUC5AC (150 µM). Green 
color corresponds to GalNAc-T2*, MUC5AC (150 µM) and MnCl2 (225 µM). Red color corresponds to GalNAc-T2* (135 µM), MUC5Ac (150 µM), MnCl2 (225 µM) 
and UDP-GalNAc (225 µM). (Right panel) Blue color corresponds to unliganded F104S*. Green color corresponds to F104S*, MnCl2 (130 µM). Red color 
corresponds to F104S*, MnCl2 (130 µM) and UDP-GalNAc (130 µM). Grey color corresponds to F104S*, MnCl2 (130 µM), UDP-GalNAc (130 µM) and MUC5Ac 
(100 µM). The concentration of GalNAc-T2* and F104S was 135 µM and 86 µM, respectively. The experiments were recorded at 298K and at 600MHz (see the 
experimental section). 
Conclusions 
Studies of naturally occurring mutations in glycosyltransferases 
that underlie human diseases or predispositions to diseases or 
other phenotypes have brought important insights into our 
understanding of this diverse group of enzymes.[14] In particular, 
studies of mutations that are not clear about how they affect 
protein structure and function have resulted in surprisingly new 
discoveries. From this perspective, our studies with the GalNAc-
T2 F104S mutant provides another excellent example. Here, we 
provide compelling evidence that the inactive-to-active state 
transition of the flexible loop in the GalNAc-T2 F104S mutant is 
hindered. The presence of the polar residue (Ser104) causes 
instability of both the flexible and the α1-α2 loops and prevents 
the flexible loop from adopting the closed conformation required 
for the active form of the enzyme. This result is further supported 
by the conservation of the Phe104, Val360 and Arg362 residues 
of the flexible loop in most GalNAc-Ts. We also predict that this 
behavior of the flexible loop will be conserved among this family 
of enzymes despite their different lengths and their partially 
different amino acid sequences. Our study has also 
experimentally demonstrated from our 19F NMR studies that 
GalNAc-T2 follows an induced-fit-mechanism in which UDP-
GalNAc is absolutely required to activate the enzyme.  
The finding that the GalNAc-T isoenzymes undergo an activation 
process induced by the donor substrate UDP-GalNAc may be an 
important factor in the regulation of the complex O-glycosylation 
process. The GalNAc-T isoenzymes not only have different, 
albeit partly overlapping, acceptor substrate specificities[9], but 
they also exhibit rather different apparent Km values for UDP-
GalNAc ranging from 10-160 µM for GalNAc-T1, T2, T3, and 
T4.[15] Provided that all the GalNAc-T isoenzymes undergo 
similar donor-induced activation, the existing differences in 
affinities for the donor substrate may serve as a regulatory 
mechanism to ensure that the many isoenzymes act in a 
required order and without a premature competitive binding to 
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the acceptor proteins. This hypothesis is also supported by the 
lower Km values for UDP-GalNAc of the first enzymes that are 
thought to initiate the O-glycosylation process, GalNAc-T1 and 
T2. These enzymes display low apparent Km values (27 and 10 
µM, respectively), while the isoenzymes involved in the follow-up 
glycosylation of the partially (GalNAc) glycosylated substrates, 
e.g. GalNAc-T4, show a much higher apparent Km for UDP-
GalNAc (160 µM).[15]  
The hexosamine biosynthetic pathway (HBP) regulates the 
cellular levels of UDP-GlcNAc and the cellular levels of UDP-
GalNAc are co-regulated with UDP-GlcNAc through 
epimerization by the UDP-Gal/UDP-GalNAc 4-epimerase.[16] As 
the levels of UDP-GlcNAc are highly dynamic, HBP is regarded 
as a nutrient-sensing pathway.[17] Therefore, it is conceivable 
that the nutrient-sensing pathway may also influence O-GalNAc 
glycosylation via changes in UDP-GalNAc concentration.  
Finally, our results have exploited the knowledge obtained from 
the structural analysis of a mutant associated with a known 
disease to obtain fundamental insights into the molecular 
mechanism of the GalNAc-T substrate recognition. Our 
multidisciplinary approach may furthermore provide the basis to 
treat low HDL-C levels through the design and implementation of 
new therapeutic strategies.  
Experimental Section 
Cloning, site-directed mutagenesis and purification. The expression 
plasmid pPICZαAgalnact2 (K75-Q571), previously described[6c] was used 
as a template for introducing the following single amino-acid changes by 
site-directed mutagenesis as follows: T375C, F104S and F104S-T375C. 
Site-directed mutagenesis was carried out using the QuikChange 
protocol (Stratagene) as recommended by the supplier. In brief, F104S 
mutation was introduced into GALNT2 codon optimized K75-Q571 ORF 
using the template pPICZαAgalnact2 (K75-Q571) and the oligo’s 
T2F104SF (3’-
TACGCAAGAAATAAGTCTAATCAGGTTGAAAGTGATAA-3’) and 
T2F104SR (5’-TTATCACTTTCAACCTGATTAGACTTATTTCTTGCGTA-
3’), generating the plasmid pPICZαAgalnact2-F104S. Note that the 
position of the mutation is underlined in the above oligos. Hereafter the 
mutation T375C was introduced by custom based mutagenesis service 
from Genewiz generating pPICZαAgalnact2-T375C and 
pPICZαAgalnact2-F104S/T375C. The expression plasmid 
pPICZαAgalnact2 (K75-Q571), previously described[6c] was used as a 
template for introducing the following single amino-acid changes by site-
directed mutagenesis as follows: F104S, T375C and F104S-T375C. Site-
directed mutagenesis was carried out following the QuikChange protocol 
(Stratagene), using the Phusion Hot Start II High-Fidelity DNA 
Polymerase (Thermo Scientific). All plasmids were verified by 
sequencing The mutants were purified using the purification protocol of 
the wild-type enzyme described previously.[6c] 
Crystallization. Crystals of the F104S mutant in complex with UDP were 
grown by sitting drop vapor diffusion at 18ºC. Crystals were obtained by 
mixing 0.5 µl of protein solution  (a mix formed by 7 mg/ml F104S mutant, 
5 mM UDP, 5 mM MnCl2, 25 mM Tris pH 7.5, 0.5 mM EDTA and 1 mM 
TCEP-HCl) with 0.5 µl of precipitant solution (10% PEG6000 and 100 
mM Hepes pH 7) against 60 µl of precipitant solution. The crystals were 
soaked within the mother liquor containing UDP-GalNAc at 50 mM for 60 
minutes. Subsequently, they were cryoprotected in mother liquor 
containing 25% ethylene glycol, 10% PEG6000 and 100 mM Hepes pH 7, 
and frozen in a nitrogen gas stream cooled to 100 K. 
Structure determination and refinement. All data were processed and 
scaled using the XDS package[18] and CCP4 software,[19] relevant 
statistics are given in Table S2. The crystal structures were solved by 
molecular replacement with Phaser[19b] and using the PDB entry 4D0T as 
the template. Initial phases were further improved by cycles of manual 
model building in Coot and refinement with REFMAC5.[20] The final 
models were validated with PROCHECK,[21] model statistics are given in 
Table S2. The asymmetric unit of the tetragonal crystals contain 2 
molecules of the inactive mutant in the AU (Figure 3). Coordinates and 
structure factors have been deposited in the Worldwide Protein Data 
Bank (wwPDB, and see Table S2 for the pdb code). 
Labeling of the mutants T375C and F104S-T375C. Both the T375C 
and the F104S-T375C variants were site-selectively modified by 
treatment with 3-bromo-1,1,1-trifluoroacetone (BFA) under mild 
conditions (5 min, phosphate buffer pH 7.0, room temperature), as 
previously described by Rydzik et al.[10]  
Solid-phase peptide synthesis. MUC5AC was synthetized as 
previously described.[5] 
Tryptophan fluorescence spectroscopy. Fluorescence spectroscopy 
was used to determine the dissociation constants of the WT enzyme and 
the F104S mutant against UDP-GalNAc. All experiments were carried out 
in a Cary Eclipse spectrofluorometer (Varian) at 25 °C with the WT 
enzyme and the F104S mutant at 1 µM, and concentrations of UDP-
GalNAc varying from 1 to 1000 µM in 25 mM Tris, 150 mM NaCl, 1 mM 
MnCl2, pH 7.5. Fluorescence emission spectra were recorded in the 300–
400 nm range with an excitation wavelength of 280 nm, with slit width of 
5 nm. The data analysis was performed in Prism (GraphPad software) 
considering a model with a single binding site (see equation (1), where 
F0 is the intrinsic fluorescence of the enzyme in the absence of quencher 
(Q), F1 is the observed fluorescence at a given quencher concentration, 
fa is the fractional degree of fluorescence and Kd is the dissociation 
constant.  
Eq 1.  
 
 
Activity assay The WT GalNAc-T2 and GalNAc-T2* activities were 
tested by incubating 100 nM of each enzyme with 10  µM MUC1 
peptide[22] and 20 µM UDP-[14C]GalNAc (2000 cpms/nm), in  25 mM 
cacodylate pH 7.4, 10 mM MnCl2, 0.25% Triton X-100. Excess of UDP-
GalNAc was separated from the glycosylated peptide trough DOWEX 1 
chromatography. The product was analyzed by scintillation counting. 
Thermal shift assays. The protein unfolding process was monitored 
using the environmentally sensitive dye 1-anilino-8-naphthalene 
sulfonate (ANS). Its quantum yield increased upon binding to 
hydrophobic surfaces exposed during protein unfolding and so does the 
fluorescence signal. The thermal-shift assay was conducted in the 
FluoDia T70 (Photal Otsuka Electronics). Solutions of 2 µM WT GalNAc-
T2 or the F104S mutant, 100 µM ANS, 20 mM HEPES pH 7.0, and 200 
mM NaCl final concentration and a volume of 100 µl were added to the 
wells of a 96-well PCR plate. Mineral oil was last added to avoid 
evaporation during the experiment. Data were analysed with the Origin 
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software. To obtain T0, a Boltzmann model from Origin was used to fit the 
fluorescence imaging data.[8] 
Molecular Dynamics simulations. MD simulations were performed 
using Amber16 and the force-field ff14SB[23] Each protein was immersed 
in a box with a 10 Å buffer of TIP3P[24] water molecules and neutralized 
by adding explicit counter ions (Cl−). A two-stage geometry optimization 
approach was used. The first stage minimizes only the positions of 
solvent molecules and ions, and the second stage is an unrestrained 
minimization of all the atoms in the simulation cell. The systems were 
then gently heated by incrementing the temperature from 0 to 300 K 
under a constant pressure of 1 atm and periodic boundary conditions. 
Harmonic restraints of 30 kcal/mol were applied to the solute, and the 
Andersen temperature coupling scheme was used to control and equalize 
the temperature. The time step was kept at 1 fs during the heating stages. 
Water molecules are treated with the SHAKE algorithm such that the 
angle between the hydrogen atoms is kept fixed. Long-range electrostatic 
effects are modeled using the particle-Mesh-Ewald method.[25] An 8-Å 
cut-off was applied to Lennard-Jones interactions. Each system was 
equilibrated for 2 ns with a 2-fs time step at a constant volume and 
temperature of 300 K. Production trajectories were then run for additional 
200 ns under the same simulation conditions.  
nLC MS/MS and data analysis. To preserve the trifluorinated compound 
at the peptide backbone, samples were not reduced and alkylated. 
GalNAcT* and F104S* were directly digested with trypsin and after 
StageTip (Empore 3M) desalting, submitted to nLC-MS/MS analysis.  
EASY-nLC 1000 UHPLC (Thermo Scientific) interfaced via nanoSpray 
Flex ion source to an Orbitrap Fusion MS (Thermo Scientific) were used 
for analysis. Briefly, the nLC was operated in a single analytical column 
set up using PicoFrit Emitters (New Objectives, 75 µm inner diameter) 
packed in-house with Reprosil-Pure-AQ C18 phase (Dr. Maisch, 1.9-µm 
particle size, 19-21 cm column length). Each sample was injected onto 
the column and eluted in a gradient from 2 to 25 % B in 45 min at 200 
nL/min (Solvent A, 100 % H2O; Solvent B, 100 % acetonitrile; both 
containing 0.1 % (v/v) formic acid). A precursor MS1 scan (m/z 350–
2,000) of intact peptides was acquired in the Orbitrap at the nominal 
resolution setting of 120.000, followed by Orbitrap HCD-MS2 and at the 
nominal resolution setting of 60.000 of the five most abundant multiply 
charged precursors in the MS1 spectrum; a minimum MS1 signal 
threshold of 50,000 was used for triggering data-dependent 
fragmentation events. Activation times were 75 ms for HCD 
fragmentation; isolation width was 1.2 mass units, and usually 1 
microscan was collected for each spectrum. Polysiloxane ions at m/z 
445.12003 were used as a lock mass in all runs. Data processing was 
performed using Proteome Discoverer 1.4 software (Thermo Scientific) 
using Sequest HT node as a search engine. In all cases the precursor 
mass tolerance was set to 10 ppm and fragment ion mass tolerance to 
20 mmu. Methionine oxidation and the trifluorinated compound at Ser/Thr 
were used as variable modifications. All spectra were searched against 
GalNAcT2* and F104S* sequences with and without mutations at the 
position 375.   
NMR experiments. NMR experiments for peptide characterization and 
saturation transfer difference NMR experiments were recorded on a 
Bruker Avance 600 MHz spectrometer equipped with a triple channel 
cryoprobe head. The 1H-NMR resonances of the peptide were assigned 
through standard 2D-TOCSY (30 and 80 ms mixing time) and 2D-
NOESY experiments (400 ms mixing time). Solution conditions used for 
the NMR characterization studies were 0.5 mM peptide in 90:10 H2O/D2O. 
The assignments were accomplished at 278K. As a chemical shift 
reference in the 1H NMR experiments we used the resonance of 2,2,3,3-
tetradeutero-3-trimethylsilylpropionic acid (TSP) (δ TSP = 0 ppm). Peak 
lists for the 2D-TOCSY and 2D-NOESY spectra were generated by 
interactive peak picking using the 
Computer Aided Resonance Assignment (CARA) software. Table S1 
contains the 1H-NMR assignment for the MUC5AC peptide. Samples for 
STD-experiments were prepared in perdeuterated 25 mM TRIS-d11 in 
deuterated water, 7.5 mM NaCl and 1 mM DTT, uncorrected pH 7.4.  
STD-NMR experiments were performed at 298 K in the presence of 75 
µM UDP, 75 µM MnCl2 with a molar ratio of 40:1 peptide:protein. The 
STD-NMR spectra were acquired with 1920 transients in a matrix with 
64k data points in t2 in a spectral window of 12335.5 Hz centered at 
2820.6 Hz. An excitation sculpting module with gradients was employed 
to suppress the water proton signals. Selective saturation of the protein 
resonances (on resonance spectrum) was performed by irradiating at −1 
ppm using a series of Eburp2.1000-shaped 90° pulses (50 ms, 1 ms 
delay between pulses) for a total saturation time of 2.0 s. For the 
reference spectrum (off resonance), the samples were irradiated at 100 
ppm. Proper STD-NMR control experiments were performed: i) with the 
ligand in absence of the protein to ensure that the ligand signals were not 
affected; ii) with the protein in absence of the ligand (data not shown). 
The peptide MUC5AC when irradiated at -1 ppm in the absence of 
protein showed residual saturation on the aliphatic methyl groups in the 
STD-NMR spectra. The STD-NMR experiments shown in this work take 
into account the STD control experiments. To obtain the STD-NMR-
derived epitope mapping the STD-NMR total intensities were normalized 
with respect the highest STD-NMR response. 19F-NMR experiments were 
recorded by 600 MHz Bruker Avance spectrometer equipped with a 
19F,1H SEF dual probe optimized for direct 19F detection. These 
experiments were carried out to monitor the 19F reporter (CF3)2COCH2- 
selectively introduced at the SH- group of the mutants T375C from both 
constructs of the WT GalNAc-T2 and the F104S mutant. The 19F 
experiments of GalNAcT2* and F104S* constructs were recorded at 
distinct conditions in absence and presence of MnCl2, UDP or UDP-
GalNAc and peptide. The UDP or UDP-GalNAc and MnCl2 were added in 
an excess of 1.5 times of the protein concentration while peptide was in a 
1.1:1 peptide:protein molar ratio.  Higher concentrations of UDP or UDP-
GalNAc (500 µM), MnCl2 (500µM) and peptide (protein:peptide molar 
ratio 1:2.2) do not induce higher 19F chemical shift perturbations. The 19F-
NMR experiments with proton decoupling were acquired at 298 K by 
acquisition of 640 scans in a matrix with 8k data points in a spectral 
window of 11295.2 Hz centered at (CF3)2CHOH -45174.9 Hz. The 
resonance of 1,1,1,3,3,3-hexafluoro-2-propanol was used as a chemical 
shift reference in the 19F NMR experiments (δ = −75.7 ppm).  Samples 
for 19F-NMR experiments were prepared in 25 mM TRIS-d11 in 90:10 
H2O/D2O, uncorrected pH 7.5. In the 19F-NMR spectra, trace amounts of 
the 3-Bromo-1,1,1-trifluoroacetone reagent used in protein labelling (δ 
CF3COCH2Br= -83.3 ppm) were observed. In addition, trace amounts of 
trifluoroacetic acid (TFA), used in the synthesis of peptides, were 
observed in the 19F-NMR spectra (δ TFA= -75.4 ppm).To monitor the 
glycosylation of MUC5AC by GalNAcT2* and F104S* two 1H-NMR 
spectra were recorded before and after the addition of UDP-GalNAc.  
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